These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37113357)

  • 1. ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report.
    Takayasu H; Kata Y; Otsu Y; Inoue S; Kaneko T
    Cureus; 2023 Mar; 15(3):e36711. PubMed ID: 37113357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
    Crvenkova S
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year Disease Control With Alectinib in a Patient With Metastatic ALK-rearranged Lung Adenocarcinoma.
    Ohara G; Sasatani Y; Okauchi S; Satoh H
    Cancer Diagn Progn; 2022; 2(6):707-710. PubMed ID: 36340452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports.
    Gozzi E; Angelini F; Rossi L; Leoni V; Trenta P; Cimino G; Tomao S
    Medicine (Baltimore); 2020 Jul; 99(27):e21004. PubMed ID: 32629718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome Inhibition Overcomes ALK-TKI Resistance in
    Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
    Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung.
    Imanishi N; Yoneda K; Taira A; Ichiki Y; Sato N; Hisaoka M; Tanaka F
    Surg Case Rep; 2018 Mar; 4(1):19. PubMed ID: 29524063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report.
    Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C
    Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
    Gu R; Shi Z; Duan T; Song M
    Onco Targets Ther; 2021; 14():5107-5113. PubMed ID: 34707369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial therapy is a safe and durable treatment option in
    Jang C; Sabari J
    Transl Lung Cancer Res; 2023 Dec; 12(12):2558-2564. PubMed ID: 38205199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
    McKeage K
    Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
    Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
    Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.
    Matsumura Y; Inomata S; Yamaguchi H; Mine H; Takagi H; Watanabe M; Ozaki Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Shio Y; Suzuki H
    Thorac Cancer; 2021 Aug; 12(15):2225-2228. PubMed ID: 34159737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
    Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of a
    Minari R; Gnetti L; Lagrasta CA; Squadrilli A; Bordi P; Azzoni C; Bottarelli L; Cosenza A; Ferri L; Caruso G; Silini EM; Tiseo M
    Transl Lung Cancer Res; 2020 Jun; 9(3):787-792. PubMed ID: 32676339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.